Literature DB >> 19250779

Safety of testosterone use in women.

Chrisandra L Shufelt1, Glenn D Braunstein.   

Abstract

Female sexual desire appears to be in part androgen dependent, which has lead to the use of testosterone in women for low libido. Despite this benefit, the long-term safety of testosterone as a hormone replacement or therapy has not been well established. Side effects of testosterone therapy include mild and reversible acne and hirsuitism, as well as changes to the lipid profile with oral, but not transdermal testosterone. Short-term studies, up to 2 years, have shown that for serum plasma testosterone levels at the upper portion or slightly above the reference range for reproductive-aged women, testosterone does not increase the risk of hepatotoxicity, endometrial hyperplasia, or behavioral hostility. No adverse cardiovascular effects including changes in blood pressure, blood viscosity, arterial vascular reactivity, hypercoagulable states, and polycythemia have been shown. Data is mixed with outcomes of breast cancer risk, with some experimental studies suggesting a decrease in estrogen-induced breast epithelial proliferation with low dose testosterone. Additionally, models of superphysiologic testosterone levels, such as polycystic ovarian disease, have not shown an increased risk of breast cancer. As with all hormone therapy in postmenopausal women, testosterone therapy should be individualized and requires that each woman weigh the risk and benefits. Nevertheless, only long-term safety studies will provide conclusive evidence as to testosterone safety in women.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19250779     DOI: 10.1016/j.maturitas.2009.01.012

Source DB:  PubMed          Journal:  Maturitas        ISSN: 0378-5122            Impact factor:   4.342


  5 in total

Review 1.  Hormone treatment and muscle anabolism during aging: androgens.

Authors:  E Lichar Dillon; William J Durham; Randall J Urban; Melinda Sheffield-Moore
Journal:  Clin Nutr       Date:  2010-05-07       Impact factor: 7.324

2.  Testosterone membrane-initiated action in breast cancer cells: Interaction with the androgen signaling pathway and EPOR.

Authors:  Vassiliki Pelekanou; George Notas; Elias Sanidas; Andreas Tsapis; Elias Castanas; Marilena Kampa
Journal:  Mol Oncol       Date:  2010-02-02       Impact factor: 6.603

Review 3.  Counseling postmenopausal women about bioidentical hormones: ten discussion points for practicing physicians.

Authors:  Richa Sood; Lynne Shuster; Robin Smith; Ann Vincent; Aminah Jatoi
Journal:  J Am Board Fam Med       Date:  2011 Mar-Apr       Impact factor: 2.657

4.  Drug utilization of Intrinsa (testosterone patch) in England: interim analysis of a prescription-event monitoring study to support risk management.

Authors:  Vicki Osborne; Lorna Hazell; Deborah Layton; Saad A W Shakir
Journal:  Drug Saf       Date:  2010-03-01       Impact factor: 5.606

5.  Could the female-to-male transgender population be donor candidates for uterus transplantation?

Authors:  Murat Api; Ayşen Boza; Mehmet Ceyhan
Journal:  Turk J Obstet Gynecol       Date:  2017-12-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.